Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if pracinostat, when given in
combination with ruxolitinib, can help to control myelofibrosis (MF). The safety of this drug
combination will also be studied.
This is an investigational study. Pracinostat is not FDA-approved or commercially available.
It is currently being used for research purposes only. Ruxolitinib is FDA-approved and
commercially available to treat MF.
The study doctor can explain how the study drugs are designed to work.
Up to 25 participants will be enrolled in this study. All will take part at MD Anderson.